-
Prospective Evaluation of Serum Free Thiols in Inflammatory Bowel Disease: A Candidate to Replace C-Reactive Protein for Disease Activity Assessment? Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-27 Anuj Bohra, Nicholas Batt, Krishneel Dutt, Pavel Sluka, Olga Niewiadomski, Abhinav Vasudevan, Daniel R Van Langenberg
Background Serum free thiols (SFTs) reflecting oxidative stress appear to correlate with inflammatory bowel disease (IBD) activity. We aimed to evaluate the performance of SFTs concentrations vs endoscopic and histological activity, compare SFTs with established biomarkers, and identify clinical and laboratory parameters independently associated with SFT levels in IBD patients. Methods Patients with
-
Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-27 Charles N Bernstein, Remo Panaccione, Zoann Nugent, Deborah A Marshall, Gilaad G Kaplan, Stephen Vanner, Levinus A Dieleman, Lesley A Graff, Anthony Otley, Jennifer Jones, Michelle Buresi, Sanjay Murthy, Mark Borgaonkar, Brian Bressler, Alain Bitton, Kenneth Croitoru, Sacha Sidani, Aida Fernandes, Paul Moayyedi
Background We aimed to establish a cohort of persons with Crohn’s disease (CD) enrolled from 14 Canadian centers to describe the contemporary presentation of CD in Canada. Methods All enrollees were at least 18 years old and underwent chart review for phenotype documentation by Montreal Classification at time of enrollment, comorbidities, inflammatory bowel disease (IBD) and other surgeries, and use
-
Accurate, Robust, and Scalable Machine Abstraction of Mayo Endoscopic Subscores From Colonoscopy Reports Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-27 Anna L Silverman, Balu Bhasuran, Arman Mosenia, Fatema Yasini, Gokul Ramasamy, Imon Banerjee, Saransh Gupta, Taline Mardirossian, Rohan Narain, Justin Sewell, Atul J Butte, Vivek A Rudrapatna
Background The Mayo endoscopic subscore (MES) is an important quantitative measure of disease activity in ulcerative colitis. Colonoscopy reports in routine clinical care usually characterize ulcerative colitis disease activity using free text description, limiting their utility for clinical research and quality improvement. We sought to develop algorithms to classify colonoscopy reports according
-
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-26 Andres J Yarur, Ryan Ungaro, Katherine Huang, Wenfei Wang, Priya Sasankan, Mir Zulqarnain, Amanda M Johnson, Geoffrey Bader, Carl Kay, Nicholas Costable, David Dulaney, Marc Fenster, Poonam Beniwal-Patel, Gaurav Syal, Anish Patel, Edward Loftus Jr, Joel Pekow, Benjamin Cohen, Parakkal Deepak
Background Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included in these trials do not represent the cohort of patients treated in the real world. In this study, we aimed to describe the effectiveness and safety of ustekinumab in a clinical cohort of patients with UC. Methods We performed a multicenter retrospective cohort study and included
-
Pan-enteric Capsule Endoscopy to Characterize Crohn’s Disease Phenotypes and Predict Clinical Outcomes in Children and Adults: The Bomiro Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-26 Salvatore Oliva, Silvio Veraldi, Giusy Russo, Marina Aloi, Fernando Rizzello, Paolo Gionchetti, Patrizia Alvisi, Flavio Labriola, Maurizio Vecchi, Pini Eidler, Luca Elli, Nikolas Dussias, Gian Eugenio Tontini, Carlo Calabrese
Background Pan-enteric capsule endoscopy (PCE) provides useful information for the management of Crohn’s disease (CD), especially in children. No study has evaluated the ability of PCE to characterize CD phenotypes and outcomes in children and adults. Methods In a prospective multicenter observational study, we recruited patients with CD >6 years from 4 centers in Italy. Patients underwent clinical
-
Healthy Lifestyle Is a Protective Factor from Moderate and Severe Relapses and Steroid Use in Inflammatory Bowel Disease: A Prospective Cohort Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-23 Sandra García-Mateo, Samuel Jesús Martínez-Domínguez, Carla Jerusalén Gargallo-Puyuelo, Beatriz Gallego, Erika Alfambra, María Escuin, Sergio García-Mateo, Julia López, Fernando Gomollón
Background A healthy lifestyle, including good adherence to a Mediterranean diet (MD) and regular physical exercise, may be an important factor during the course of inflammatory bowel disease (IBD). Our aim is to determine whether adherence to MD, physical activity, and the combination of both can impact on IBD course. Methods This prospective cohort study includes 693 IBD outpatients who were in remission
-
Continuous Monitoring of CRP, IL-6, and Calprotectin in Inflammatory Bowel Disease Using a Perspiration-Based Wearable Device Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-23 Sarah Shahub, Ruchita Mahesh Kumar, Kai-Chun Lin, Ivneet Banga, Natalie K Choi, Nicole M Garcia, Sriram Muthukumar, David T Rubin, Shalini Prasad
Background Wearable sensor devices represent a noninvasive technology to continuously track biomarkers linked to inflammatory bowel disease (IBD). We assessed the inflammatory markers associated with IBD in human perspiration. Methods Participants with IBD were monitored for 40 to 130 minutes with a proprietary wearable sensor device used to measure C-reactive protein, interleukin-6, and calprotectin
-
The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-22 Iria Bastón-Rey, Iago Rodríguez-Lago, Ana María Luque, Berta Caballol, Carlos Soutullo-Castiñeiras, Ana Bravo, Andrés Castaño, Beatriz Gros, Lorena Bernal, María Teresa Diz-Lois, Horacio Alonso-Galán, Fiorella Cañete, Beatriz Castro, Pablo Pérez-Galindo, Carlos González-Muñoza, Ismael El Hajra, Pilar Martínez-Montiel, Inmaculada Alonso-Abreu, Francisco Mesonero, María González-Vivo, Laia Peries, Eduardo
Background Limited data are available on the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). We describe the natural history of pre-existing IBD and de novo IBD after SOT. Methods This was a retrospective, multicenter study that included patients with pre-existing IBD at the time of SOT and patients with de novo IBD after SOT. The primary outcome was
-
Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn’s Disease Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-21 Vipul Jairath, Theresa Hunter Gibble, Alison Potts Bleakman, Kaitlin Chatterton, Paolo Medrano, Megan McLafferty, Brittany Klooster, Sonal Saxena, Richard Moses
Background Bowel urgency is bothersome in patients with ulcerative colitis (UC) or Crohn’s disease (CD) and impacts their well-being but remains underappreciated in clinical trials and during patient–healthcare provider interactions. This study explored the experiences of bowel urgency and bowel urgency-related accidents to identify the concepts most relevant and important to patients. Methods Adults
-
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-20 Johannes Plechschmidt, Konstantin Fietkau, Tobias Hepp, Peter Dietrich, Sarah Fischer, Sabine Krebs, Markus F Neurath, Frank Dörje, Raja Atreya
Background Antitumor necrosis factor (anti-TNF) antibody treatment has led to marked improvements in the management of patients with inflammatory bowel diseases (IBDs). Nevertheless, anti-TNF therapy is associated with potential adverse drug reactions (ADRs). Our prospective, randomized trial investigated the effect of intensified clinical pharmacist counselling in a multidisciplinary team on medication
-
Attenuation of Colitis-Induced Visceral Hypersensitivity and Pain by Selective Silencing of TRPV1-Expressing Fibers in Rat Colon Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-13 Yoav Mazor, Nurit Engelmayer, Halla Nashashibi, Lisa Rottenfußer, Shaya Lev, Alexander M Binshtok
Background Transient receptor potential vanilloid 1 (TRPV1) cation channels, expressed on nociceptors, are well established as key contributors to abdominal pain in inflammatory bowel disease (IBD). Previous attempts at blocking these channels have been riddled with side effects. Here, we propose a novel treatment strategy, utilizing the large pore of TRPV1 channels as a drug delivery system to selectively
-
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-09 Bruce E Sands, Geert D’Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Background Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative colitis. Results are presented from the open-label extension study through W104. Methods Clinical, symptomatic, quality-of-life, and adverse event outcomes are reported
-
Antibacterial Agents May Have Shifted Impacts on Inflammatory Bowel Diseases Along with Decrease in Gut Bacteria Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-08 Xiaofa Qin
Lay Summary This article discussed the likely bell-shaped complicated impacts of antibacterial agents such as food additives like some artificial sweeteners on inflammatory bowel diseases including ulcerative colitis and Crohn’s disease along with decrease in gut bacteria.
-
Inflammatory Bowel Disease and Breastfeeding: A Narrative Review Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-05 Tedi Hoxha, Michael Youssef, Vivian Huang, Parul Tandon
Inflammatory bowel disease (IBD) frequently affects women of childbearing age who may consider breastfeeding. Although breastfeeding has numerous benefits, there remain concerns regarding the safety of breastfeeding among women with IBD. Breastfeeding is important in developing the immune system of infants and has been shown to protect against the development of IBD. The risk of developing an increase
-
Risk of Infection in Patients With Inflammatory Bowel Disease Treated With Interleukin-Targeting Agents: A Systematic Review and Meta-Analysis Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-01 Konstantinos Ouranos, Hira Saleem, Stephanos Vassilopoulos, Athanasios Vassilopoulos, Evangelia K Mylona, Fadi Shehadeh, Markos Kalligeros, Bincy P Abraham, Eleftherios Mylonakis
Background Patients with inflammatory bowel disease (IBD) are at increased risk of infection. The aim of this study was to assess the cumulative incidence and risk of infection in patients with IBD treated with interleukin (IL)-targeting agents. Methods We searched PubMed, EMBASE, and Web of Science for randomized controlled trials including patients with IBD receiving IL-targeting agents compared
-
Feasibility and Acceptability of Digital Behavioral Interventions Among Black and Hispanic Patients With Inflammatory Bowel Disease: A Randomized Pilot Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-03-01 Ruby Greywoode, Shadi Nahvi, Thomas Ullman, Laurie Keefer
Lay Summary The use of digital behavioral interventions was tested among patients with inflammatory bowel disease with a predominately low-income, Black/Hispanic background who had elevated symptoms of anxiety/depression. Both mood-tracking and cognitive behavioral self-management applications were feasible and acceptable to use, with opportunities for improvement identified.
-
Our Life Is a Rollercoaster! A Qualitative Phenomenological Study Exploring the Impact of IBD on Family Members Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-28 Parichat Thapwong, Christine Norton, Emma Rowland, Wladyslawa Czuber-Dochan
Background Inflammatory bowel disease (IBD) significantly impacts patients and their families. To provide support, understanding the effects on the wider family is crucial. However, limited research exists on the impact of IBD on family members of adults diagnosed with IBD. This study addresses this knowledge gap. Methods Underpinned by interpretive phenomenology, this study used in-depth, semi-structured
-
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-28 A Swaminathan, G M Borichevsky, C M Frampton, A S Day, M B Hampton, A J Kettle, R B Gearry
Background Biomarkers have been proposed as surrogate treatment targets for the management of inflammatory bowel disease (IBD); however, their relationship with IBD-related complications remains unclear. This study investigated the utility of neutrophil biomarkers fecal calprotectin (fCal) and fecal myeloperoxidase (fMPO) in predicting a complicated IBD course. Methods Participants with IBD were followed
-
Comorbidity Between Inflammatory Bowel Disease and Asthma and Allergic Diseases: A Genetically Informed Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-27 Tong Gong, Bronwyn K Brew, Cecilia Lundholm, Awad I Smew, Arvid Harder, Ralf Kuja-Halkola, Jonas F Ludvigsson, Yi Lu, Catarina Almqvist
Background Little is known about shared origins between inflammatory bowel disease (IBD) and allergic diseases (asthma, allergic rhinitis, and eczema). We aimed to expand current knowledge on the etiological sources of comorbidities between these disorders using a range of genetically informed methods. Methods Within-individual and familial co-aggregation analysis was applied to 2 873 445 individuals
-
Clinical Outcomes at 8-16 Weeks After Upadacitinib Initiation for Acute Severe Ulcerative Colitis: A Case Series in the United States Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-26 Rahul S Dalal, Rachel W Winter, Sanchit Gupta, Gila F Sasson, Matthew J Hamilton, Jessica R Allegretti
Lay Summary In 9 patients hospitalized for acute severe ulcerative colitis, 8 were successfully discharged without the need for colectomy. Six of 7 patients with sufficient follow-up achieved steroid-free clinical remission at 8 to 16 weeks, and 1 of 2 patients achieved endoscopic response.
-
Causal Association Analysis of Periodontitis and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-26 Xiangli Qing, Chenhui Zhang, Zhuotai Zhong, Tao Zhang, Lin Wang, Shuangshuang Fang, Tianyuan Jiang, Xiaoying Luo, Yang Yang, Gengqing Song, Wei Wei
Background Periodontitis has been reported to be associated with inflammatory bowel disease (IBD), including ulcerative colitis (UC), and Crohn’s disease (CD). However, the causality of these 2 diseases remains unclear. We conducted bidirectional Mendelian randomization (MR) to investigate the causal relationship between periodontitis and IBD. Methods We obtained the genome-wide association study (GWAS)
-
Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom Over the Last 10 Years Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-19 Zachary Green, James J Ashton, Astor Rodrigues, Christine Spray, Lucy Howarth, Akshatha Mallikarjuna, Neil Chanchlani, James Hart, Christopher Bakewell, Kwang Yang Lee, Amar Wahid, R Mark Beattie
Background Pediatric inflammatory bowel disease (pIBD) incidence has increased over the last 25 years. We aim to report contemporaneous trends across the South West United Kingdom. Methods Data were provided from centers covering the South West United Kingdom (Bristol, Oxford, Cardiff, Exeter, and Southampton), with a total area at-risk population (<18 years of age) of 2 947 534. Cases were retrieved
-
Health Services Utilization and Specialist Care in Pediatric Inflammatory Bowel Disease: A Multiprovince Population-Based Cohort Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-17 M Ellen Kuenzig, Alain Bitton, Matthew W Carroll, Anthony R Otley, Harminder Singh, Gilaad G Kaplan, Therese A Stukel, David R Mack, Kevan Jacobson, Anne M Griffiths, Wael El-Matary, Laura E Targownik, Geoffrey C Nguyen, Jennifer L Jones, Sanjay K Murthy, Charles N Bernstein, Lisa M Lix, Juan Nicolás Peña-Sánchez, Trevor J B Dummer, Sarah Spruin, Stephen G Fung, Zoann Nugent, Stephanie Coward, Yunsong
Background Patterns of health services utilization among children with inflammatory bowel disease (IBD) are important to understand as the number of children with IBD continues to increase. We compared health services utilization and surgery among children diagnosed <10 years of age (Paris classification: A1a) and between 10 and <16 years of age (A1b). Methods Incident cases of IBD diagnosed <16 years
-
Vedolizumab Does Not Affect Antibody Secreting Cell Recruitment to the Lactating Mammary Gland of Mothers With Inflammatory Bowel Disease Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-09 Josef Urrete, Taniya Mitra, Brigid S Boland, Kerri Bertrand, Christina Chambers, Jesús Rivera-Nieves
Lay Summary Despite a known role for α4β7 and MAdCAM-1 for the recruitment of antibody secreting cells to the lactating mammary gland, vedolizumab which targets integrin α4β7 did not lower breastmilk IgA in lactating mothers with IBD receiving the drug. It is likely that antibody secreting cells alternatively employ α4β1 to arrest on VCAM-1 also expressed by the lactating mammary gland.
-
Thrombocytosis and Transaminitis in Infants Born to Women With Inflammatory Bowel Disease Is Associated With Exposure to Maternal Inflammation In Utero Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-08 Ralley Prentice, Emma Flanagan, Emily Wright, Winita Hardikar, Alyson Ross, Megan Burns, Lani Prideaux, William Connell, Miles Sparrow, Peter De Cruz, Mark Lust, Rimma Goldberg, Sara Vogrin, Tessa Greeve, Sally Bell
Background Despite reassuring clinical safety data, thrombocytosis, anemia, lymphopenia, and liver function derangements have been observed in infants born to women with inflammatory bowel disease (IBD) treated with thiopurines and biologics. We aimed to define the prevalence, course, associations, and clinical impact of hematological and biochemical abnormalities in such infants. Methods This multicenter
-
Physical Activity and IBD: State of Art and Knowledge, Patients and Healthcare Professionals Points of View, A French Multicenter Cross Sectional Study Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-08 Lea Derbey, Anne Laure Charlois, Anthony Buisson, Xavier Roblin, Nicolas Mathieu, Pauline Danion, Claire Gay, Stéphane Nancey, Gilles Boschetti
Background Several studies have reported low levels of physical activity (PA) in patients with inflammatory bowel diseases (IBD), possibly related to a lack of information and support, despite the many recognized benefits such as cardiovascular prevention or quality of life (QoL) improvement. Methods The purpose of our study was to identify challenges faced by patients and to evaluate IBD impact on
-
Predictors of Complicated Disease Course in Adults and Children With Crohn’s Disease: A Nationwide Study from the epi-IIRN Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-08 Ohad Atia, Rona Lujan, Rachel Buchuk, Shira Greenfeld, Revital Kariv, Yiska Loewenberg Weisband, Natan Ledderman, Eran Matz, Oren Ledder, Eran Zittan, Henit Yanai, Doron Shwartz, Iris Dotan, Daniel Nevo, Dan Turner
Background Since data on predictors of complicated Crohn’s disease (CD) from unselected populations are scarce, we aimed to utilize a large nationwide cohort, the epi-IIRN, to explore predictors of disease course in children and adults with CD. Methods Data of patients with CD were retrieved from Israel’s 4 health maintenance organizations, whose records cover 98% of the population (2005-2020). Time-to-event
-
Ion Transport Basis of Diarrhea, Paneth Cell Metaplasia, and Upregulation of Mechanosensory Pathway in Anti-CD40 Colitis Mice Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-02-01 Dulari Jayawardena, Arivarasu N Anbazhagan, Apurba Majumder, Ramsha Akram, Ali Nazmi, Ramandeep Kaur, Anoop Kumar, Seema Saksena, Danyvid Olivares-Villagómez, Pradeep K Dudeja
Background Anti-Cluster of differentiation (CD)-40-induced colitis, driven by innate inflammatory responses in the intestine, is a potent animal model exhibiting IBD pathophysiology including diarrhea. However, the ion transport basis of diarrhea and some key mucosal pathways (Paneth cells, stem cell niche, and mechanosensory) in this model have not been investigated. Methods Mucosal scrapings and
-
Crohn’s Disease–Associated Pathogenic Mutation in the Manganese Transporter ZIP8 Shifts the Ileal and Rectal Mucosal Microbiota Implicating Aberrant Bile Acid Metabolism Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-30 Kristi Briggs, Vartika Tomar, Nicholas Ollberding, Yael Haberman, Arno R Bourgonje, Shixian Hu, Lara Chaaban, Laxmi Sunuwar, Rinse K Weersma, Lee A Denson, Joanna M P Melia
Background A pathogenic mutation in the manganese transporter ZIP8 (A391T; rs13107325) increases the risk of Crohn’s disease. ZIP8 regulates manganese homeostasis and given the shared need for metals between the host and resident microbes, there has been significant interest in alterations of the microbiome in carriers of ZIP8 A391T. Prior studies have not examined the ileal microbiome despite associations
-
Unveiling Colitis: A Journey through the Dextran Sodium Sulfate-induced Model Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-27 Chunhua Yang, Didier Merlin
Animal models of inflammatory bowel disease (IBD) are valuable tools for investigating the factors involved in IBD pathogenesis and evaluating new therapeutic options. The dextran sodium sulfate (DSS)-induced model of colitis is arguably the most widely used animal model for studying the pathogenesis of and potential treatments for ulcerative colitis (UC), which is a primary form of IBD. This model
-
Breaking Down Barriers: Epithelial Contributors to Monogenic IBD Pathogenesis Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-27 Jodie D Ouahed, Alexandra Griffith, Lauren V Collen, Scott B Snapper
Monogenic causes of inflammatory bowel diseases (IBD) are increasingly being discovered. To date, much attention has been placed in those resulting from inborn errors of immunity. Therapeutic efforts have been largely focused on offering personalized immune modulation or curative bone marrow transplant for patients with IBD and underlying immune disorders. To date, less emphasis has been placed on
-
FIBER-DEFICIENT DIET INHIBITS COLITIS THROUGH REGULATION OF THE NICHE AND METABOLISM OF A GUT PATHOBIONT Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Peter Kuffa, Joseph Pickard, Austin Campbell, Sadie Schaus, Jeremy Adler, Eric Martens, Tom Schmidt, Naohiro Inohara, Gabriel Núñez, Roberta Caruso
Fiber free exclusive enteral nutrition (EEN) is an effective steroid-sparing treatment used to induce clinical remission in children with Crohn’s disease (CD). However, the mechanism underlying the beneficial effects of EEN remains obscure. We have generated a novel mouse strain that harbors mutations in two CD susceptibility genes (i.e, NOD2 and CYBB) and found that these mice spontaneously develop
-
MITOCHONDRIAL DYSFUNCTION CAUSES CECAL PATCH (CP) INFLAMMATION IN ULCERATIVE COLITIS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Parth H Patel, Syed Adeel Hassan, Ahmad Kasem, Lesley Wempe, Mohamed Elsayed, Sarayu Bhogoju, Tatiana Goretsky, Goo Lee, Terrence Barrett, Neeraj Kapur
BACKGROUND Up to 17% of distal ulcerative colitis (UC) patients have discontinuous (proximal) inflammation referred to as Cecal Patch (CP), associated with greater abdominal pain, bleeding and diarrhea. Despite these known associations, the pathogenesis of CP lesions is poorly understood. Recent data suggest that reduced mitochondrial (Mito) function predicts unfavorable clinical outcomes in active
-
THE IMPACT OF TREATMENT SWITCH AMONG PATIENTS WITH ULCERATIVE COLITIS NEWLY TREATED WITH A BIOLOGIC – A JAPAN RETROSPECTIVE CLAIMS DATABASE STUDY Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Ana Dubon Garcia, Myrlene Sanon, Jin Yu Tan, Celine Miyazaki, DaeYoung Yu, Zhao Jing
INTRODUCTION Biologics have largely expanded treatment options for ulcerative colitis (UC) patients. Despite advanced treatments, up to 50% of patients treated with any biologic also suffer loss of response or intolerance. This study assessed the healthcare resource utilization (HCRU) associated with treatment switch as an indicator of suboptimal treatment of UC in patients newly treated with a biologic
-
EVOLVING LANDSCAPE OF INFLAMMATORY BOWEL DISEASE IN G20 NATIONS (1990-2019): A COMPREHENSIVE GLOBAL ASSESSMENT Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Rahul Patel, Krishna Sajeev, Vani Sojitra, Krina Manojbhai Patel, Pranathi Royal Naradasu, Sneh Patel, Hardik Dineshbhai Desai
BACKGROUND As pivotal players in the global economy, the G20 countries not only lead in economic dynamics but also in health challenges. Recent data reveals an escalating burden of Inflammatory Bowel Disease (IBD) in these nations. Understanding this trend is crucial to frame healthcare strategies and ensure the well-being of a significant portion of the global population. METHOD We employed data on
-
POLYMER-BASED INTERFACE TARGETING INFLAMMATION IN ULCERATIVE COLITIS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Sufeng Zhang, Amy Jin, Jochen Lennerz, Joshua Korzenik, Carlo Traverso
A major hurdle in the treatment of inflammatory bowel disease (IBD) is the lack of effective drug carriers that can precisely deliver the required amount of drug to the sites of inflammation. Available therapies have limited efficacy or severe side effects, largely because of the low concentration of active drugs at the disease sites and non-specific systemic absorption of the administered drugs. Drug
-
ENHANCED MITOCHONDRIAL BIOGENESIS INCREASES ANTI-OXIDANT ENZYMES AND IMPROVES TISSUE INFLAMMATION IN HUMAN IBD TISSUE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Sarayu Bhogoju, Neeraj Kapur, Hemendra Vekaria, Tatiana Goretsky, Syed Adeel Hassan, Jong Hyun Kim, Samuel Awuah, Patrick Sullivan, Luksana Chaiswing, Terrence Barrett
BACKGROUND In patients with inflammatory bowel disease (IBD), there exists a connection between mitochondrial dysfunction and two key issues: increased oxidative stress and attenuated ATP production. Previously we presented at this meeting the effect of a novel gold-based compound (AuPhos) on enhancing mitochondrial function in attenuating mice colitis (). In the present study we interrogate the effect
-
3D MORPHOGENESIS AND BACTERIAL CO-CULTURE IN A CANINE GUT-ON-A-CHIP USING BIOPSY-DERIVED INTESTINAL ORGANOIDS FROM HEALTHY AND IBD PATIENTS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Itsuma Nagao, Meg Nakazawa, Yoko Ambrosini
The understanding of the role of intestinal bacteria in various intestinal diseases has been limited due to the lack of suitable in vitro models. However, recent advancements in Gut-on-a-Chip culture technology provide a promising avenue for exploring complex interactions between intestinal epithelium and bacteria. In this study, we aimed to create a microfluidic Gut-on-a-Chip co-culture system using
-
UNDERSTANDING HOW PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS DESCRIBE THE SPECTRUM OF BOWEL URGENCY DEFINITIONS: RESULTS FROM QUALITATIVE RESEARCH Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Marla Dubinsky, Theresa Hunter, Larissa Stassek, Gale Harding, Marissa Stefan, Tsion Fikre, Alison Potts Bleakman, Richard Moses
BACKGROUND Bowel urgency, the sudden or immediate need to have a bowel movement, is a burdensome symptom to patients with ulcerative colitis (UC). The objective of this study was to understand how adult patients with moderately-to-severely active UC describe bowel urgency remission and “no or minimal” bowel urgency. METHODS Qualitative phone interviews were conducted with adults with HCP-confirmed
-
LEUCINE-RICH ALPHA 2 GLYCOPROTEIN: A USEFUL BIOMARKER TO DISCRIMINATE SMALL INTESTINAL MUCOSAL HEALING IN C-REACTIVE PROTEIN-NEGATIVE CROHN’S DISEASE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Akihito Tanaka, Shuji Kanmura, Nobuhisa Maeda, Kosuke Kuwazuru, Fukiko Komaki, Yuga Komaki, Akio Ido
BACKGROUND The treatment goals for inflammatory bowel disease, including Crohn's disease (CD), have shifted from clinical remission to mucosal healing. However, frequent endoscopies burden patients. Leucine-rich alpha 2 glycoprotein (LRG), produced by hepatocytes, neutrophils, and the intestinal epithelium, is more gut-specific than C-reactive protein (CRP). We examined whether LRG, as a biomarker
-
IMPACT OF TREATMENT RESPONSE WITH ADALIMUMAB ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH CROHN’S DISEASE: SECONDARY ANALYSIS OF THE PYRAMID REGISTRY Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Dhruv Ahuja, Jiyu Luo, Yuchen Qi, Gaurav Syal, Brigid Boland, John Chang, Christopher Ma, Vipul Jairath, Ronghui Xu, Siddharth Singh
BACKGROUND AND AIMS Treatment efficacy and safety are primary factors in choosing therapies in patients with Crohn’s disease (CD). However, they can be perceived to be at odds with each other with more potent therapies associated with increased risk of infections. We evaluated the impact of treatment response on the risk of serious infections in adalimumab-treated patients with CD through secondary
-
INFLAMMATION-TRIGGERED CLAUDIN-23 DOWNREGULATION IMPACTS INTESTINAL EPITHELIAL BARRIER FUNCTION Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Arturo Raya-Sandino, Kristen Lozada-Soto, Vicky Garcia-Hernandez, Charles Parkos, Asma Nusrat
Intestinal epithelium maintains gut homeostasis by protecting the underlying tissue compartments from harmful contents. Although it is suggested that epithelial barrier function compromise contributes to the pathogenesis of inflammatory bowel disease (IBD), the underlying mechanisms are not well understood. Claudins (CLDN) are tight junctions (TJ) proteins that determine epithelial barrier properties
-
INFLIXIMAB AND ITS BIOSIMILARS FOR INFLAMMATORY BOWEL DISEASE: ANALYSIS OF MEDICARE PART D CLAIMS AND COSTS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Modan Goldman, Vedant Jain, Nafisa Mostofa, Davendra Ramkumar
INTRODUCTION Inflammatory Bowel Disease (IBD) presents a multifaceted healthcare challenge, and biologics have emerged as crucial in its management. The introduction of biosimilars, designed to enhance cost-efficiency and access, has garnered significant attention. This analysis of the Medicare Part D database assesses trends in total drug claims and costs for infliximab and its biosimilars, specifically
-
MACHINE LEARNING CLASSIFICATION OF THE EPIDEMIOLOGIC STAGES OF INFLAMMATORY BOWEL DISEASE ACROSS GEOGRAPHY AND TIME Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Lindsay Hracs, Joseph Windsor, Julia Gorospe, Michael Buie, Joshua Quan, Lea Caplan, Ante Markovinovic, Michael Cummings, Quinn Goddard, Tyler Williamson, Yvonne Abbey, Maria Abreu, Raja Ali, Murdani Abdullah, Mansour Altuwaijri, Vineet Ahuja, Domingo Balderramo, Rupa Banerjee, Eric Benchimol, Charles Bernstein, Eduard Brunet-Mas, Johan Burisch, Vui Heng Chong, Iris Dotan, Usha Dutta, Sara El Ouali
BACKGROUND Epidemiologic stages of inflammatory bowel disease (IBD) have been proposed: 1. Emergence (low incidence and prevalence); 2. Acceleration in Incidence (rapidly rising incidence, low prevalence); and 3. Compounding Prevalence (stabilizing incidence, rapidly rising prevalence). To date, these stages have been theoretical without quantified definitions of incidence and prevalence. AIM To use
-
INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRY Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Samantha Paglinco, Mahmoud Abdel-Rasoul, Megan McNicol, Brendan Boyle, Jennifer Dotson, Hilary Michel, Ross Maltz
BACKGROUND Biologic medications have transformed treatment for autoimmune conditions, including inflammatory bowel disease (IBD), but have also contributed to rising healthcare expenditures in the United States (US). Biosimilars, which are highly similar in safety and efficacy to the originator biologic, were introduced to create competition and reduce cost. Limited studies exist evaluating the impact
-
PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG ADVANCED THERAPY-NAÏVE PATIENTS WITH ULCERATIVE COLITIS INITIATED ON USTEKINUMAB OR ADALIMUMAB Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Sumesh Kachroo, Maryia Zhdanava, Sabree Burbage, Porpong Boonmak, Aditi Shah, Jill Korsiak, Patrick Lefebvre, Caroline Kerner, Dominic Pilon
BACKGROUND In the real-world setting, biologic therapy in patients with ulcerative colitis (UC) may require dose escalation if initial response is limited or due to loss of response. Dose escalation leads to higher treatment costs and may cause difficulties obtaining prior authorization and approvals from health plans. This study compared treatment persistence while on labeled maintenance dose among
-
EVOLVING BURDEN OF INFLAMMATORY BOWEL DISEASE IN WOMEN FROM 1990-2019: GLOBAL, REGIONAL, NATIONAL VARIATIONS, AGE DYNAMICS, AND IMPLICATIONS FOR GLOBAL HEALTH Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Vani Sojitra, Pranathi Royal Naradasu, Krina Manojbhai Patel, Rahul Patel, Sneh Patel, Hardik Dineshbhai Desai
BACKGROUND Inflammatory Bowel Disease (IBD), encompassing conditions such as Crohn's disease and ulcerative colitis, has been a growing concern globally. While its burden has been studied extensively, the specific impact on women, who face unique physiological and socio-cultural challenges, remains underexplored. Grasping the global, national, and regional implications of IBD in women across 204 countries
-
PATTERNS AND ASSOCIATED FACTORS OF OBJECTIVE INFLAMMATION ASSESSMENT TO TREAT-TO-TARGET: DATA FROM THE IBD QORUS COLLABORATIVE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Thien-Bao Nguyen, Corey Siegel, Gil Melmed, Siddharth Singh, Sarah Harvey, Ridhima Oberai, Jason Hou, David Fudman
BACKGROUND A Treat-to-Target (T2T) strategy for inflammatory bowel disease (IBD) improves clinical outcomes. The cornerstone of T2T is the routine assessment of objective markers of inflammation to determine treatment efficacy. Despite this, objective testing is often delayed or not performed. This study aims to describe patterns and associated factors of intended assessment of objective markers of
-
MAINTENANCE EFFICACY OF ORAL INDIGO NATURALIS FOR ULCERATIVE COLITIS: A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Yuichi Matsuno, Junji Umeno, Atsushi Hirano, Yuta Fuyuno, Tomohiro Nagasue, Shin Fujioka, Keisuke Kawasaki, Tomohiko Moriyama, Takehiro Torisu
BACKGROUND Indigo naturalis (IN) is one of the herbal medicines in Chinese medicine. Recent reports have demonstrated a strong remission induction efficacy of oral IN in induction therapy for ulcerative colitis (UC), but the efficacy of IN in maintenance therapy for UC is unknown. OBJECTIVES We aimed to clarify the maintenance effect of IN. METHODS A single-center, open-label, randomized, controlled
-
MRI AND BLOOD-BASED BIOMARKERS ASSOCIATED WITH SURGICAL MANAGEMENT IN CHILDREN AND ADULTS WITH SMALL BOWEL CROHN'S DISEASE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Jonathan Dillman, Joel G Fletcher, David Bruining, Subra Kugathasan, Ryan Stidham, Jeremy Adler, Jean Tkach, Adina Alazraki, Jack Knight-Scott, Aiming Lu, Bruce Trapnell, Scott Swanson, Lin Fei, Alexander Towbin, Murat Kocaoglu, Christopher Anton, Rebecca Imbus, Jonathan Dudley, Lee Denson
BACKGROUND Despite advances in medical therapy, many children and adults with ileal Crohn’s Disease (CD) progress to fibrostenosis requiring surgery. Prior studies have identified circulating and imaging biomarkers associated with strictures, although their associations with need for surgery are not well-established. PURPOSE We aimed to identify MRI and circulating biomarkers associated with the need
-
EFFECTS OF NUTRITION STATUS AND PERIOPERATIVE NUTRITION SUPPLEMENT COMPLETION ON POSTOPERATIVE OUTCOMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING SURGERY Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Stacey Collins, Viankail Cedillo Castelan, Rebecca Wernick, Andrea Banty, Colleen Gwarnicki, Theodore Solomon, Lilly Martirosyan, Pamela Roberts, Andrea Wise, Melissa Hampton, Yosef Nasseri, Karen Zaghiyan, Phil Fleshner, Gil Melmed, Kelly Issokson
BACKGROUND Malnutrition is common in inflammatory bowel disease, (IBD) and is associated with poor disease activity, greater hospital length of stay (LOS), higher 30-day readmission rates, and increased risk of postoperative complications. Structured, multimodal prehabilitation including nutrition counseling improves various outcomes after elective cancer and orthopedic surgeries. We examined the effects
-
INFLAMMATORY BOWEL DISEASE AND RHEUMATOID ARTHRITIS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Evelyn Calderon Martinez, Esmeralda Vilchez, Wern Lynn Ng, Seema Sharma Gautam, Diana Gavilanes, Maria Joseph, Christian Zevallos-Delgado
Inflammatory bowel disease has been associated with arthritis since the late 20th century, but it was not until a few decades ago that IBD-associated arthritis was recognized as a distinct pathology independent from rheumatoid arthritis (RA). There is evidence that RA and other autoimmune conditions exist in higher rates in patients with IBD compared to the general population. This is an important
-
VISUALIZING HETEROGENEOUS TRAJECTORIES OF SUBJECTS WITH SURGICAL RELAPSE IN INFLAMMATORY BOWEL DISEASE FROM UK BIOBANK GENERAL PRACTICE DATA Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Kingsley Njoku, Akira Koseki, Akihiro Kosugi, Tesfaye Yadete, Joao Bettencourt-Silva, Alberto Purpura, Natasha Mulligan, Uri Kartoun, Eileen Koski, Vibha Anand, Thaddeus Stappenbeck, Julia Liu
BACKGROUND AND AIMS The United Kingdom (UK) Biobank (UKBB) is a large-scale biomedical database and research resource, containing in-depth health information from half a million participants in UK that have been used for detailed analyses of IBD. Using the UKBB, we examined the lab findings and prescription medication use in IBD subjects to identify trajectory patterns of disease with respect to surgical
-
ASSOCIATION OF HIDRADENITIS SUPPURATIVA AND INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Natchaya Polpichai, Angkawipa Trongtorsak, Chudapa Sereeaphinan, Pojsakorn Danpanichkul, Phuuwadith Wattanachayakul, Panu Wetwittayakhlang
INTRODUCTION Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic inflammatory skin condition that affects apocrine gland-bearing areas. Previous studies have demonstrated that HS is potentially associated with various autoimmune diseases. However, the relationship between HS and inflammatory bowel disease (IBD) has been unclear. METHODS A comprehensive literature search was conducted
-
COST-DRIVERS OF HEALTHCARE EXPENDITURES IN INFLAMMATORY BOWEL DISEASE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Jeffrey Berinstein, Gil Melmed, John Allen, Sameer Berry
INTRODUCTION Inflammatory bowel diseases (IBD) are gastrointestinal (GI) conditions associated with significant costs. Effective management of IBD should focus on improving patient symptoms and outcomes while containing healthcare costs. To develop high-value treatment strategies and influence policy on high-value care, we must first have a better understanding of the primary drivers of cost in this
-
DECREASED HEALTHCARE UTILIZATION IN UNINSURED PATIENTS WITH PERIANAL CROHN’S DISEASE UNDERGOING PROCTECTOMY Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Vladislav Izda, Yonatan Israel, Monica Feeley, Regina Longley, Esther Kim, Nikhil Maheshwari, Cecilia Katzenstein, Patricia Sylla, Sergey Khaitov, Alexander Greenstein, Serre-Yu Wong
INTRODUCTION Perianal Crohn's disease (CD) is a debilitating subtype affecting nearly 20% of CD patients, primarily characterized by the presence of perianal fistulas. It is associated with poor health outcomes, significantly decreased quality of life, and is an independent predictor of work disability. Proctectomy is generally reserved for patients with severe, refractory disease. Social determinants
-
IHIBITION OF TRNA QUEUOSINE MODIFICATION CAUSE MITOCHONDRIAL DYSFUNCTION AND APOPTOSIS IN THE INTESTINAL EPITHELIAL CELLS Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Di Ran, Yong-guo Zhang, Jun Sun
BACKGROUND Transfer RNA (tRNA) modifications occur through the action of specific enzymes that recognize and modify the nucleotides within the tRNA molecule. Queuine tRNA-ribosyltransferase catalytic subunit 1 (QTRT1) and QTRT 2 co-localize in mitochondria and form a heterodimeric TGT participating in tRNA Queuosine (tRNA-Q) modification. Our previous study demonstrated that Q-tRNA modification plays
-
NANOPARTICLE ENCAPSULATION OF THE SPECIALIZED PRO-RESOLVING MEDIATOR MARESIN-2: A NOVEL APPROACH FOR PROMOTING MUCOSAL REPAIR IN THE INTESTINE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Jael Miranda-Guzman, Aaron Morris, Miguel Quiros, Jennifer Brazil, Charles Parkos, Asma Nusrat
Epithelial cells form protective barriers at mucosal surfaces and play a critical role in maintaining tissue homeostasis. Active inflammation in inflammatory bowel disease (IBD) is associated with epithelial barrier disruption and mucosal erosions/wounds that contribute to the inflammatory response and disease symptoms. Therefore, efficient repair of epithelial erosions/wounds is crucial for restoring
-
UNCOVERING UNIQUE NEEDS AND BARRIERS TO CARE AMONG LGBTQ+ PATIENTS WITH IBD: INSIGHTS FROM A COMMUNITY SURVEY TO INFORM INCLUSIVE PRACTICES Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Victor Chedid, Alicia Aiello, Chelsie Anderson Chadha, Jeffrey Carter, Laura Simone, Jennifer Balmer
INTRODUCTION Lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ+) individuals face a myriad of disparities and unique challenges that impact their clinical care and outcomes, however, less is known regarding the specific needs of sexual and gender minorities with inflammatory bowel disease (IBD). Methods: The aim of this study was to better understand the unmet needs and potential barriers
-
ROUTINELY COLLECTED BLOODWORK REVEALS IMMUNE CELL PATTERNS THAT REFLECT DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE Inflamm. Bowel Dis. (IF 4.9) Pub Date : 2024-01-25 Peyton Briand, Daniel Mulder
OBJECTIVE The standard procedure for evaluation of inflammatory bowel disease (IBD) diagnosis and activity requires endoscopy, but there have been many biomarkers identified that are associated with IBD and are collected much less invasively. White blood cell subsets, also known as “the differential”, is a commonly used test for patients with IBD, but the relationship between the differential and disease